Caribou Biosciences to Participate in Upcoming Investor Conferences
August 31 2022 - 4:05PM
Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage
CRISPR genome-editing biopharmaceutical company, today announced
the company’s participation in the following investor conferences:
- Citi 17th Annual
BioPharma Conference, BostonPanel participation on
September 8, 2022, 11:20 am ETWebcast
- H.C. Wainwright 24th
Annual Global Investment Conference, New York
CityCorporate presentation on September 13, 2022, 10:00 am
ETWebcast
- Morgan Stanley 20th
Annual Global Healthcare Conference, New York
CityFireside chat on September 13, 2022, 4:40 pm ETWebcast
- Jefferies Cell and Genetic Medicines Summit,
New York CitySeptember 29-30, 2022; see Events page for
details
For more information, visit the Events page on
Caribou’s website. Webcasts will be available on the Caribou
website for 30 days after the event.
About Caribou’s Novel Next-Generation
CRISPR PlatformCRISPR genome editing uses easily designed,
modular biological tools to make DNA changes in living cells. There
are two basic components of Class 2 CRISPR systems: the nuclease
protein that cuts DNA and the RNA molecule(s) that guide the
nuclease to generate a site-specific, double-stranded break,
leading to an edit at the targeted genomic site. CRISPR systems are
capable of editing unintended genomic sites, known as off-target
editing, which may lead to harmful effects on cellular function and
phenotype. In response to this challenge, Caribou has developed
CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”)
that direct substantially more precise genome editing compared to
all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA
technology to carry out high efficiency multiple edits, including
multiplex gene insertions, to develop CRISPR-edited therapies.
About Caribou Biosciences,
Inc.Caribou Biosciences is a clinical-stage CRISPR
genome-editing biopharmaceutical company dedicated to developing
transformative therapies for patients with devastating diseases.
The company’s genome-editing platform, including its proprietary
Cas12a chRDNA technology, enables superior precision to develop
cell therapies that are specifically engineered for enhanced
persistence. Caribou is advancing a pipeline of off-the-shelf CAR-T
and CAR-NK cell therapies for the treatment of patients with
hematologic malignancies and solid tumors.
For more information about Caribou, visit
www.cariboubio.com and follow the company @CaribouBio.
“Caribou Biosciences” and the Caribou logo are
registered trademarks of Caribou Biosciences, Inc.
Caribou Biosciences, Inc.
Contacts:Investors:Amy Figueroa,
CFAafigueroa@cariboubio.com
Media:Peggy Vorwald,
Ph.D.pvorwald@cariboubio.com
Investors and Media: Elizabeth
Wolffe, Ph.D., and Sylvia WheelerWheelhouse LSA
lwolffe@wheelhouselsa.comswheeler@wheelhouselsa.com
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jun 2024 to Jul 2024
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jul 2023 to Jul 2024